

*陳仁熙醫師

所有發表期刊論文及報告

1. **Chen JS**, Wang JM, Liaw CC, Ng KT, Ho YS: Klinefelter's syndrome associated with mediastinal germ cell tumor: report of a case. J Chinese Oncol Soc 6: 21-25, 1990
2. Kiu MC, Hsueh S, Ng SH, **Chen JS**: Elevated serum CA-125 in tuberculous peritonitis: report of a case. J Formos Med Assoc 93: 816-818, 1994
3. Huang JS, Liaw CC, **Chen JS**, Fang KM, Yen CL, Lai GM: Combinant chemotherapy with a modified schedule of etoposide, adriamycin and cisplatin (EAP) regimen for advanced gastric adenocarcinoma. J Chinese Oncol Soc 10: 12-21, 1994
4. **Chen JS**, Liaw CC, Wang HM, Tsai MH, Hao SP, Hsueh S: Osteosarcoma of jaw: the experience of Chang Gung Memorial Hospital. Chang Gung Med J 18: 260-265, 1995
5. Kiu MC, Chang CN, Cheng WC, Lin TK, Wong CW, Tang SG, Leung WM, **Chen JS**, Lai GM et al: Combination chemotherapy with carmustine and cisplatin before, during, and after radiotherapy for adult malignant gliomas. J Neuro Oncol 25:215-220, 1995.
6. Wang HM, Wang CH, **Chen JS**, Chang HK, Kiu MC, Liaw CC, Ng KT, Lai GM: Cisplatin and 5-fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer. J Formos Med Assoc 94: 87-94, 1995
7. Ho YS, Hsieh LL, **Chen JS**, Chang CN, Lee ST, Chiu LL, Chin TY, Cheng SC: p53 gene mutation in cerebral primitive neuroectodermal tumor in Taiwan. Cancer Lett 1996 Jun 24;104(1):103-113.
8. Wang CH, Wang HM, **Chen JS**, Chang WJ, Lai GM: Intensive chemotherapy plus recombinant human granulocyte-colony

stimulating factor support for distant metastatic nasopharyngeal carcinoma. *Oncology* 54:34-37, 1997

9. Liaw CC, Wang CH, Huang JS, Kiu MC, **Chen JS**, Chang HK: Serum lactate dehydrogenase level in patients with nasopharyngeal carcinoma. *Acta Oncol* 36: 159-164, 1997
10. Cheng YT, Huang CT, Leu HS, **Chen JS**, Kiu MC: Central nervous system infection due to clostridium septicum: a case report and literature review. *Infection* 25: 171-174, 1997
11. Liaw CC, Chuang CK, **Chen JS**, Chang HK: Gastric cancer with obstructive uropathy: clinical experience with 17 cases. *Chang Gung Med J* 20: 286-292, 1997.
12. **Chen JS**, Lai GM, Hsueh S: Malignant thyroid teratoma of an adult: a long-term survival after chemotherapy. *Am J Clin Oncol* 21: 212-214, 1998
13. **Chen JS**, Jan YY, Lin YC, Wang HM, Chang WC, Liao CT: Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with biliary tract carcinomas. *Anti-Cancer Drugs* 9: 393-397, 1998
14. Liaw CC, **Chen JS**, Wang CH, Chang HK, Huang JS: Tumor fever in patients with nasopharyngeal carcinoma: clinical experience of 67 patients. *Am J Clin Oncol* 21: 422-425, 1998.
15. Chung CM, Chu PH, **Chen JS**, Hsueh C, Chiang CW: Primary pericardial mesothelioma with cardiac tamponade and distant metastasis: case report. *Chang Gung Med J* 21: 498-502, 1998.
16. Liaw CC, Wang HM, Wang CH, Yang TS, **Chen JS**, Chang HK, Lin YC, Liaw SJ, Yeh CT: Risk of transient hyperammonemia encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. *Anti-Cancer Drugs* 10: 275-281, 1999.

17. **Chen JS**, Liu HE, Wang CH, Yang TS, Wang MH, Liao CH, Chang WH, Lin YC: Weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced gastric cancer. *Anti-Cancer Drugs*, 10: 355-359, 1999.
18. Wang HM, Wang CH, **Chen JS**, Su CL, Liao CT, Chen IH: The impact of oral submucous fibrosis on the chemotherapy-induced mucositis for the head and neck cancer in a geographic area in which betel quid chewing is prevalent. *Am J Clin Oncol* 22: 485-488. 1999.
19. Lin YC, Liu HE, Wang CH, Wang HM, Yang TS, Liao CT, **Chen JS***. Clinical benefit and response in patients with gastric cancer to weekly 24-hour infusion of high-dose 5-fluorouracil (5-FU) and leucovorin(LV). *Anticancer Research* 19: 5615-5620, 1999.
20. Yang TS*, Lin YC, **Chen JS**, Wang HM, Wang CH. Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. *Cancer* 89; 750-6, 2000.
21. Lin YC*, Hsien-Kun Chang, Wang CH, **Chen JS**, Liaw CC. Single-agent docetaxel in metastatic breast cancer patients pretreated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel. *Anti-Cancer Drugs* 11; 617-621, 2000.
22. Yeow KM*, Wang CH, Liaw CT, **Chen JS**, KO Wu, PN Wang. The groshong peripheral inserted central (PIC) catheter: initial experience with ultrasound-guided insertion. *中華民國放射線醫學會雜誌* 24; 61-66, 2000.
23. Yeow KM*, Tan CF, **Chen JS**, Hsueh C. Diagnostic sensitivity of ultrasound-guided needle biopsy in soft tissue masses about superficial bone lesions. *J Ultrasound Med* 19: 849-55, 2000.

24. Wang HM*, Wang CH, Liaw CT, **Chen JS**, Yang TS, Chen IH. Intra-arterial plus intravenous chemotherapy for advanced bulky Squamous cell carcinoma of buccal mucosa. *Anti-Cancer Drugs* 12; 331-7, 2001.
25. **Chen JS***, Lin YC, Jan YY, et al. Mitomycin C with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. *Anti-Cancer Drugs* 12; 339-43, 2001.
26. Lin YC*, **Chen JS**, et al. Weekly high-dose 5-fluorouracil, leucovorin and biweekly cisplatin in patients with advanced gastric cancer. *Jpn J Clin Oncol* 31(12): 605- 09, 2001.
27. Pan KY, Lin JL*, **Chen JS**. Severe reversible bone marrow suppression induced by *Selaginella doederleinii*. *Clinical Toxicology*. 39(6): 637-39, 2001.
28. Wang SH*, Hsieh CC, Chao TC, Jan YY, Jeng LB, Hwang TL, Chen MF, Chen PC, **Chen JS**, Hsueh S. Resectable gastric cancer: operative and survival analysis. *Chang Gung Med J*. 25(4): 228-37, 2002.
29. Wang HM*, CH Wang, **Chen JS**, Chen IH, Liao CT, Chang TCJ. Cisplatin, tegafur and leucovorin: A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally squamous cell carcinoma of the head and neck. *Cancer* 94; 2898-95, 2002.
30. Yang TS*, Wang JY, Tang R, Hsu KC, **Chen JS**. Oral uracil/tegafur UFT plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucorvin for the treatment of metatstatic colorectal cancer. *Jpn J Clin Oncol* 32(9): 352-357, 2002.
31. Yang TS*, CH Wang, Hsieh RK, **Chen JS**, Fung MC. Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. *Ann Oncol* 2002(13); 1771-78.

32. Liaw CC*, Chang HK, Liao CT, Huang JS, Lin YC, **Chen JS**. Reduced maintenance of complete protection from emesis for women during chemotherapy cycles. *Am J Clin Oncol* 2003 (26): 12-15.
33. **Chen JS***, Lin YC, Wang CH, Liaw CC. Mitomycin with weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced gastric cancer. *Chang Gung Med J*, 2003; 26 (June): 433-39,
34. Lin MH. **Chen JS**, Chen HH, Su WH*. A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinoma. *Chemotherapy*, 2003 (49): 154-158.
35. **Chen JS***, Yang TS, Lin YC, Jan YY. A phase II trial of tegafur-uracil and uracil in the treatment of advanced biliary tract carcinomas. *Jpn J Clin Oncol* 2003 ; 33(7): 353-356.
36. Hsu C, Shen YC, Yang CH, Yeh KH, Lu YS, Hsu CH, Liu TY, Li CC, **Chen JS**, Wu CY, Cheng AL*. Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract. *Brit J Cancer* 2004; 90:1715-1719.
37. Sheen WC, **Chen JS**, Wang HM, Yang TS, Liaw CC, Lin YC*. A modified low-dose regimen of mitoxantrone and prednisolone in patients with androgen-independent prostate cancer. *Jpn J Clin Oncol* 2004; 34(6): 337-341.
38. **Yang** TS*. Chang HK. **Chen JS**. Lin YC. Liao CT. Chang WC. Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. *Journal of Gastroenterology*. 39(4):362-9, 2004.
39. **Chen JS***, Huang JS, Yang TS, Lin YC, Wang HM, Liao CT, Rau KM. Phase I dosing-escalating study of oxaliplatin in combination with oral tegafur-uracil and leucovorin in patients with advanced gastric cancer. *Anti-Cancer Drugs*, 2005;16: 47-51.

40. CT Liao, Chu NM, Liu HE, Deuson R, Lien J, Chen JS*. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcome. Supportive Care in Cancer, 2005;13(5): 277-286.
41. CC Liaw*, CG Wang, HS Chang, HM Wang, JS Huang, YC Lin, JS Chen. Cisplatin-related hiccupc: male predominance, induction by desamethasone, and protection against nausea and vomiting. J of Pain & Symptom Management, 2005; 30 (No 4): 359-366.
42. WC Chou, SM Jung, Chen JS*, Spontaneous intracranial tumor bleeding from metastatic hepatocellular carcinoma: a case report. J. Chinese Oncol Soc 2004; 20 (2): 10-21. (publication on Oct 26, 2005)
43. YC Lin, HK Chang, Chen JS, HM Wang, TS Yang and CC Liaw. A Phase II randomized study of two Taxanes and Cisplatin for metastatic breast cancer after anthracycline: A final analysis. Jpn J Clin Oncol 2007; 37: 23-29.
44. Lin YC*, Chang KH, Shen WC, Chen JS, Wang HM. An open-labeled phase II trial of docetaxel in combination with cisplatin as first-line cytotoxic therapy for anthracycline-naïve patients with metastatic breast cancer. Anti-Cancer Drugs 2007, 18: 1213-19.
45. Chou WC. Lu CH. Lin G. Hong YS. Chen PT. Hsu HC. Chen JS. Yeh KY. Wang HM. Liaw CC*. Transcutaneous arterial embolization to control massive tumor bleeding in head and neck cancer: 63 patients' experiences from a single medical center. Supportive Care in Cancer. 15(10):1185-90, 2007 Oct.
46. Chu Z. Chen JS. Liao CT. Wang HM. Lin YC. Yang MH. Chen PM. Gardner ER. Figg WD. Sparreboom*. A. Oral bioavailability of a novel paclitaxel formulation (Genetaxyl) administered with cyclosporin A in cancer patients. Anti-Cancer Drugs. 19(3):275-81, 2008 Mar.

47. Liaw CC, **Chen JS***, Chang HK, Huang JS, Yang TS, Liao CT. Symptoms and signs of port-related infections in oncology patients related to the offending pathogens. *Int J of Clinic Practice* 2008; 62: 1193-8.
48. Hsu HC, Chang HK, Lin YC, Hseu C, **Chen JS**, Yang TS, Wang HC, Shen YC*. The role of HER2 in metastatic breast cancer treated with a combination of taxanes and cisplatin. *Chang Gung Medical J*, 2009; 32 (1): 33-41.
49. Tang ST*, Wu SC, Hung YN, Huang EW, **Chen JS**, Liu TW. Trends in quality of end-of-life care for Taiwanese cancer patients who died in 2000–2006. *Ann Oncol* 2009; 20: 343-349
50. **Chen JS***, Rau KM, Chen YY Huang JS, Yang TS, Lin YC, Liao CT, Lee KD, Su TC, Kao RH. A multiple-center phase II study of biweekly oxaliplatin and tegafur- uracil/ leucovorin for chemo-naïve patients with advanced gastric cancer. *Cancer Chemother Pharmacol* 2009; 63: 818-825.
51. Ch'ang HJ, Huang CL, Wang HP, Shiah HS, Chang MC, Jan CM, **Chen JS**, Tien YW, Hwang TL, Lin JT, Cheng AL, Whang-Peng J, Chen LT*. Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer. *Cancer Chemother Pharmacol* 2009; 64: 1173-9.
52. **Chen JS***, Chao Y, Yang TS, Chou WC, Chen LT, Lee KD, Lin YC. A phase II trial of biweekly oxaliplatin with simplified schedule of 48-h infusion of high-dose 5-fluorouracil and leucovorin for advanced biliary tract carcinoma. *Cancer Chemother Pharmacol*. 2009; 65: 151-57.
53. Tang ST*, WuSC, Hung YN, **Chen JC**, Huang EW, Liu TW. Determinants of Aggressive End-of-Life Care for Taiwanese Cancer Decedents, 2001 to 2006. *J Clin Oncol* 2009 : 4613-18.
54. **Chen JS**, Wang HM, Wu SC, Liu TW, Hung YN, Tang ST*. A population-based study on the prevalence and determinants of

cardiopulmonary resuscitation in the last month of life for Taiwanese cancer decedents, 2001-2006. Resuscitation 2009; 80: 1388-93.

55. Liu TW, **Chen JS**, Wang HM, Wu SC, Hung YN, Tang ST*. Quality of end-of-life care between medical oncologists and other physician specialists for Taiwanese cancer decedents, 2001-2006. Oncologist. 2009 Dec; 14 (12):1232-41
56. Tang ST*, Huang EW, Liu TW, Wang HM, **Chen JS**. A population-based study on the determinants of hospice utilization in the last year of life for Taiwanese cancer decedents, 2001-2006. Psych-Oncology 2010 Jan 29 [Epub ahead of print]
57. Wu SC, **Chen JS**, Wang HM, Hung YN, Liu TW, Tang ST. Determinants of ICU care in the last month of life for Taiwanese cancer decedents, 2001-2006. Chest 2010 Apr 2. [Epub ahead of print]
58. Bang YJ*, Kang YK, Kang WK, Bok N, Chung HC, **Chen JS**, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011 Dec;29(6):1449-58
59. **Chen JS**, Chao Y, Bang YJ, Roca E, Chung HC, Palazzo F, Kim YH, Myrand SP, Mullaney BP, Shen LJ, Lin C*. A phase I/II and pharmacogenomic study of pemetrexed and cisplatin in patients with unresectable, advanced gastric carcinoma. Anti-Cancer Drugs. 2010 Sep, 21 (8):777–784
60. **Chen JS**, Chao Y, Hsieh RK, Cheng AL, Chen PM, Chiou TJ, Chao TY, Yeh KH, Chen LT, Whang-Peng J*. A phase II and pharmacokinetic study of first line S-1 for advanced gastric cancer in Taiwan. Cancer Chemother Pharmacol. 2011; 67: 1281-89
61. Liaw CC*, Huang JS, **Chen JS**, Chang JW, Chang HK, Liao CT. Using vital sign flow sheets can help to identify neoplastic fever and other possible

causes in oncology patients: a retrospective observational study. J Pain Symptom Manage. 2010 Aug; 40(2):256-65.

62. Tang ST*, Tang WR, Liu TW, Lin CP, **Chen JS**. What really matters in pain management for terminally ill cancer patients in Taiwan. Journal of Palliative Care 26:3 / 2010; 151–158.

63. Tang ST, Huang EW, Liu TW, Wang HM, Rau KM, **Chen JS**. Aggressive End-of-Life Care Significantly Influenced Propensity for Hospice Enrollment Within the Last Three Days of Life for Taiwanese Cancer Decedents. J Pain Symptom Manage. 2010 Sep 7. [Epub ahead of print]

64. Wang LH, Tsai YF, **Chen JS**, Tsay PK. Intension, needs, and expectations of cancer patients participating in clinical trials. Cancer Nurs. 2011 Mar-Apr; 34(2):117-23.

65. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, **Chen JS**, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10;364(6):501-13

66. Ch'ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, **Chen JS**, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT. Induction Chemotherapy with Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients with Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study. Int J Radiat Oncol Biol Phys. 2011 Dec 1; 81(5):e749-57. Epub 2011 Mar 21..

67. Shen WC, Yang TS, Hsu HS, **Chen JS (Correspondence)** . A Phase II Study of Irinotecan in Combination With Cisplatin as Second-line Chemotherapy in

Patients with Metastatic or Locally Advanced Gastric Cancer. Chang Gung Med J. 2011 Nov; 34(6):590-8.

68. **Chen JS**, Chen YY, Huang JS, Yeh KY, Chen PT, Shen WC, Hsu HC, Lin YC, Wang HM. A multiple-centre phase II study of weekly docetaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer. Gastric Cancer 2012; 15 (Jan): 49-55.
69. Wang HM, Koong LS, Hsiao SH, **Chen JS**, Liu TW, Tang ST. Impact of Availability of an Inpatient Hospice Unit on the Parent Hospital's Quality of Palliative Care for Taiwanese Cancer Decedents, 2001-2006. J Pain Symptom Manage 2011;42:400- 409
70. Yeh CN, Chen YY, Tseng JH, **Chen JS**, Chen TW, Tsai CY, Cheng CT, Jan YY, Chen MF. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Transl Oncol. 2011 Dec; 4(6):328-35. Epub 2011 Dec 1.
71. Liu TW, Chang WC, Wang HM, **Chen JS**, Koong SL, Hsiao SC, Tang ST. Use of chemotherapy at the end of life among Taiwanese cancer decedents, 2001-2006. Acta Oncol. 2012 Jan 27. [Epub ahead of print]
72. Chou WC, Hung YS, Hsu JT, **Chen JS**, Lu CH, Hwang TL, Rau KM, Yeh KY, Chen TC, Sun CF. Chromogranin A is a Reliable Biomarker for Gastroenteropancreatic Neuroendocrine Tumors in an Asian Population of Patients. Neuroendocrinology. 2012; 95: 344-50.
73. Wu CN, Hsu HC, Shen WH, Lin YC, Wang HM, Chang JWC, **Chen JS** **(Correspondence)** The Experience of Chemotherapy with Gemcitabine Plus Cisplatin in Patients with Advanced Biliary Tract Carcinoma in Chang Gung Memorial Hospital: A Retrospectively Analysis. Chang Gung Med J. 2012 Sep-Oct 35(5): 420-7.

74. Kim YH, Muro K, Yasui H, **Chen JS**, Ryu MH, Park SH, Chu KM, Choo SP, Sanchez T, DelaCruz C, Mukhopadhyay P, Lainas I, Li PC. A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. *Cancer Chemother Pharmacol*. 2012 Oct;70(4):583-90. Epub 2012 Aug 12.
75. Cheng WH, Kao CY, Hung YS, Su PJ, Hsieh CH, **Chen JS**, Wang HM, Chou WC. Validation of Palliative Prognostic Index to Predict Life Expectancy for Terminally Ill Cancer Patients in Hospice Consultation Setting in Taiwan *Asian Pacific J Cancer Prev*, 2012; 13, 1-6
76. Hung YS, Chang H, Wu WS, **Chen JS**, Chou WC. A Comparison of Cancer and Noncancer Patients who Receive Palliative Care Consultation Services. *Am J Hosp Palliat Care*. 2012 Oct 3. [Epub ahead of print]
77. Hung YS, Wu JH, Chang H, Wang PN, Kao CY, Wang HM, Liao CT, **Chen JS**, Lin YC, Su PJ, Hsieh CH, Chou WC. Characteristics of Patients With Hematologic Malignancies Who Received Palliative Care Consultation Services in a Medical Center. *Am J Hosp Palliat Care*. 2013 Jan 8. [Epub ahead of print]
78. Chou WC, Hung YS, Kao CY, Su PJ, Hsieh CH, **Chen JS**, Liao CT, Lin YC, Liaw CC, Wang HM. Impact of palliative care consultative service on disease awareness for patients with terminal cancer. *Support Care Cancer*. 2013 Feb 21. [Epub ahead of print]
79. Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, **Chen JS**, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study. *J Clin Oncol*. 2013 Apr 1. [Epub ahead of print]
80. Lee KC, Chang WC, Chou WC, Su PJ, Hsieh CH, **Chen JS**, Tang ST. Longitudinal Changes and Predictors of Caregiving Burden While Providing End-of-Life Care for Terminally Ill Cancer Patients. *J Palliat Med*. 2013 Apr 4. [Epub ahead of print]

Presentations:

1. Small cell carcinoma of unknown primary. The annual meeting of Chinese Oncology Society, Taipei, May 1996.
2. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patients with metastatic pancreaticobiliary tract cancer, The annual meeting of Chinese Oncology Society, Taipei, May 1997.
3. Clinical response, Quality of Life and Clinical Benefit in patients with metastatic gastric cancer treated with weekly high dose 24-hour infusion 5-FU and Leucovorin.
5th Sino-Japan symposium for cancer treatment: gastric cancer from basic to clinic. Taipei, Oct. 1997. (invited speaker)
4. Weekly high dose 24-hour infusion 5-FU and Leucovorin in patients with metastatic biliary tract cancer. 4th Asia-Pacific Cancer Conference(APCC), Hong Kong, Nov, 1997.
5. A validation of different clinical response criteria for gastric cancer with weekly high-dose 5-fluorouracil and leucovorin 24-hr continuous therapy. 34th annual meeting of American Society of Clinical Oncology, Los Angeles, May 1998.
6. Cisplatin, tegafur, & leucovorin: An effective, nontoxic, and outpatient neoadjuvant chemotherapy for squamous cell carcinoma of the head and neck. 35th annual meeting of American Society of Clinical Oncology, Atlanta, May 1999.
7. Mitomycin with 24-hr high-dose of 5-FU & LV in patient with advanced biliary tract cancer. Annual meeting of Chinese Oncology Society, May 2000.
8. The chemotherapy for advanced gastric cancer- Chang Gung Memorial Hospital experience. 4th Terry-Fox International Cancer Symposium. Oct 21, 2000. Linkuo, Taiwan.
9. Mitomycin with 24-hr high-dose of 5-FU & LV in patient with advanced gastric cancer. 4th Asia Society of Clinical Oncology and Annual meeting of Chinese Oncology Society, April 2001. Taipei, Taiwan.

10. A phase II study of Gemcitabine for patients with advanced biliary tract and periampullary cancers. Elly Lilly Local regional Oncology Meeting, Hong Kong, March 9-10, 2002. (invited speaker)
11. A phase II trial of tegafur-uracil and uracil in the treatment of advanced biliary tract carcinomas. The annual meeting of Chinese Oncology Society, Taipei, July, 2003.
12. Phase I dosing-escalating study of oxaliplatin in combination with oral tegafur-uracil / leucovorin in patients with advanced gastric cancer. Gastrointestinal Cancer symposium by American Society of Clinical Oncology, San Francisco, Jan 21, 2004.
13. Efficacy and Safety for Phase I/II Study of Biweekly OXA and Tegafur-Uracil /LV for Advanced Gastric Cancer. The 2005 ISGO Gastrointestinal Oncology Conference, Arlington, Virginia, USA. July 14, 2005.
14. A Multiple Center Phase II Study of Biweekly Oxaliplatin (OXA) and tegafur- Uracil / Leucovorin (LV) in Chemonaïve Patients With Advanced Gastric Cancer.
7th Asian Clinical Oncology Society Annual Meeting, Sep 13-15, 2006. Beijing, China
15. A phase II trial of oxaliplatin with high-dose of 5-FU/LV in the first line treatment of inoperable, locally advanced or metastatic biliary tract cancer. 14th European Conference of Cancer (ECCO), Sep 23-27, 2007. Barcelona, Spain.
16. A Pharmacokinetic and Phase II Study of S-1 as First Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer. 2008 Gastrointestinal Cancers Symposium. Jan 25-27, 2008, Orlando, Florida, USA
17. A Phase II Study of Irinotecan (Irinotecan) in Combination with Cisplatin as Second Line Chemotherapy in Patients with Metastatic or Locally

Advanced Gastric Cancer. The 13th Taiwan Joint Cancer Conference, May 3 –4, 2008. Taipei, Taiwan.

18. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients with Advanced Gastric Cancer: Preliminary Report of Feasibility Analysis. The 13th Taiwan Joint Cancer Conference, May 3 –4, 2008. Taipei, Taiwan.

19. A Pharmacokinetic and Phase II Study of S-1 as First Line Chemotherapy in Patients with Locally Advanced or Metastatic Gastric Cancer. Final report (oral report). The 13th Taiwan Joint Cancer Conference, May 3 , 2008. Taipei, Taiwan.

20. The Role Of Oxaliplatin And Docetaxel in The Treatment Of Advanced Gastric Cancer (invited speaker). The 13th Taiwan Joint Cancer Conference, May 4 , 2008. Taipei, Taiwan

21. Practice and perspective of chemotherapy for advanced gastric cancer. (invited speaker) Satellite International Symposium of 81st Annual meeting of Japan Gastric Cancer Association. March 8, 2009, Kyoto, Japan.

22. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients with Advanced Gastric Cancer: 14th Taiwan Joint Cancer Conference, May 3 , 2008. Taipei, Taiwan. May2- 3 , 2009, Taipei, Taiwan.

23. A Phase II Study of Weekly Eloxatin Combined with Taxotere as First-Line Treatment in Patients with Advanced Gastric Cancer: ECCO14-34. ESMO Sep 20-24, Berlin, German.

24. Management of Malignant Functional Pancreatic Neuroendocrine Tumor with Somatostatin Analogue. Taiwan Pancreatic Neuroendocrine Tumor meeting, Taipei, Oct. 2009

25. The Chemotherapy in Patient With Biliary Tract Cancer: Experience of Chang Gung Memorial Hospital. The Japan-Taiwan joint symposium on Medical Oncology. Nov 2009.(Invited speaker)

26. Octreotide Long-acting Release for Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors - An Experience in Chang Gung Memorial Hospital. May 2010 Taiwan Joint Cancer Conference
27. Octreotide Long-acting Release for Patients with Functional Gastroenteropancreatic Neuroendocrine Tumors - An Experience in Chang Gung Memorial Hospital. Euoperan neuroendocrine tumor meeting, 2012 March.
28. Clinical Implication of Biomarker in GEP-NET Management: May 2012. Taiwan Joint Cancer Conference (Invited speaker)

References:

1. Lee-Yung Shih, M.D.
Professor
Division of Hematology-Oncology
Department of Internal Medicine
Chang Gung Memorial Hospital
Taipei, Taiwan.
2. Yi-Yin Jan, MD
Chief & Professor,
Department of General Surgery,
Chang Gung Memorial Hospital.
Taipei, Taiwan.
3. Siew -Tzuh Tang, D.N. Sc.,
Professor,
Graduate School of Nursing,
Chang Gung University,
259 Wen-Hwa 1st Road, Kwei-Shan,
Tao-Yuan, Taiwan

4. Chang-Chi Liaw, MD
Clinical Professor
Division of Hematology-Oncology
Department of Internal Medicine
Chang Gung Memorial Hospital
Taipei, Taiwan.